Eli Lilly's Weight-Loss Pill Foundayo Clears UK Approval, Two Months Behind Novo Nordisk's Wegovy Pill

Britain's medicines regulator cleared Eli Lilly's weight-loss pill Foundayo on Monday, August 10, for both weight management and type 2 diabetes, according to Reuters. The UK is the first country in Europe to approve the drug for both conditions.

The chemical name is orforglipron. It's a once-daily, small-molecule GLP-1 pill, and unlike some rivals, patients can take it anytime, without food or water restrictions, according to emjreviews.com. Julian Breach, an executive director at the Medicines and Healthcare products Regulatory Agency, said the MHRA is "pleased to be the first regulator in Europe to authorise this tablet for weight management and type 2 diabetes," as reported by The Motley Fool.

Lilly is not the first to market. Novo Nordisk's Wegovy pill beat it to UK approval by two months, back in June. Novo's pill has already racked up more than 5 million prescriptions worldwide since its January launch, and roughly 300,000 UK patients started it within the first three weeks, according to Novo Nordisk CEO Mike Doustdar, cited by Yahoo Finance. Doustdar said he can picture a future where obesity treatment becomes "to a large extent, a pill market."

The Money and the Timeline

A Lilly spokesperson told Reuters that Foundayo will launch in the UK later this month through private prescription. It will carry a lower list price than Lilly's injectable Mounjaro, which runs about £330 a month. The spokesperson didn't give exact pricing.

Here's the catch: the MHRA was explicit that "whilst this tablet is approved for use in the UK, it is not available currently via the NHS." Reimbursement isn't automatic. Lilly still needs to clear a National Institute for Health and Care Excellence (NICE) cost-effectiveness appraisal, with a decision expected November 18, 2026, according to emjreviews.com. Until then, most UK patients pay out of pocket.

Foundayo is also still under review in the European Union. Novo's Wegovy pill already has a positive recommendation from the European Medicines Agency, with the European Commission's final approval decision still pending, per Reuters reporting carried by both wmbdradio.com and whbl.com.

The Clinical Numbers

The phase 3 data behind Foundayo is substantial. In the ATTAIN-1 trial, 3,127 adults with obesity took orforglipron for 72 weeks. At the 36 mg dose, average weight loss hit 11.2%, versus 2.1% for placebo, and 54.6% of participants lost at least 10% of their body weight, according to emjreviews.com.

In a separate trial, ACHIEVE-1, involving 559 people with early type 2 diabetes, HbA1c dropped 1.47 to 1.48 percentage points at the higher doses by week 40, compared to 0.41 points for placebo. Gastrointestinal side effects were the most common complaint across both studies, mostly mild to moderate and concentrated during dose escalation.

Wall Street's Read

Lilly's US sales tell a mixed story. Foundayo brought in $98 million in US sales last quarter, and Lilly raised its full-year 2026 revenue guidance to $85 billion to $87 billion on strong GLP-1 demand, according to Yahoo Finance. But Lilly CEO David Ricks has acknowledged Foundayo's US uptake has been slower than Wegovy's pill rollout, which he attributes to the time it takes a brand-new medicine to earn trust with doctors and patients.

Fox News framed the broader GLP-1 boom bluntly: Lilly's stock jumped over 7% on soaring Mounjaro and Zepbound demand, with hosts Stuart Varney and Taylor Riggs flagging that the diet-drug wave is already denting food companies like Kraft Heinz through lower sales volume.

The Compounding Fight in the Background

None of this competition is happening in a vacuum. Novo Nordisk has also gone to court against telehealth company Hims & Hers, alleging illegal marketing of compounded semaglutide copies that infringe its patents, which run through 2032, according to Breitbart's reporting of CNBC coverage. Novo's group general counsel, John Kuckelman, called the compounded products "untested" and said mass compounding puts patients at risk. Hims called the suit "a blatant attack" on Americans' access to affordable care.

That's an unresolved legal fight, not a resolved one. No court ruling has been issued as of this writing. Hims already pulled its own oral obesity copycat product days before the suit, after federal scrutiny mounted, and its stock dropped more than 18% on the news while Novo shares rose over 3% in Copenhagen.

The bigger question hanging over both Lilly and Novo isn't really about the UK approval. It's whether patients and NHS reviewers, once NICE issues its cost-effectiveness ruling in November, decide a pill is worth the switch from injectables that already have years of prescribing history behind them.